Prism Medico and Pharmacy Limited is an Indian listed entity currently undergoing a significant strategic transformation. Historically rooted in financial services and specialized trading, the company has pivoted its core focus toward the pharmaceutical, life sciences, and healthcare sectors. Headquartered in **Kala Amb, Himachal Pradesh**, the company operates as a **single-segment** entity without any **subsidiaries, associates, or joint ventures**, ensuring a streamlined corporate structure. --- ### **Strategic Pivot: Life Sciences and Healthcare Expansion** Following a formal alteration of its **Memorandum of Association (MoA)** in **FY 2022-23**, the company has transitioned into the high-growth life sciences domain. The current operational scope includes: * **Pharmaceutical Manufacturing:** Processing, formulating, and refining **antibiotics, drugs, and biologicals**. * **Wellness & Nutraceuticals:** Development and trade of **ayurvedic products, dietary supplements**, and vaccines. * **Specialized Trading:** Wholesale and retail distribution of medicinal preparations, chemicals, and restoratives. * **Professional Financial Services:** Leveraging historical expertise to provide **Finance and Accounting Outsourcing (FAO)** and **Corporate Finance** advisory, including business valuations and debt syndication. --- ### **Capital Structure and Growth Funding** To support its entry into new market segments and meet working capital requirements, the company has executed a substantial capital infusion strategy. The **Authorized Capital** was recently increased from **Rs. 10 Crore** to **Rs. 25 Crore** (comprising **2.5 Crore** equity shares at **Rs. 10** each). **Summary of Recent Fundraise (Preferential Allotment)** | Instrument | Number of Securities | Issue Price (per unit) | Total Aggregate Value | | :--- | :--- | :--- | :--- | | **Equity Shares** | **7,500,000** | **Rs. 20** (incl. **Rs. 10** premium) | **Rs. 15,00,00,000** | | **Convertible Warrants** | **5,000,000** | **Rs. 20** (incl. **Rs. 10** premium) | **Rs. 10,00,00,000** | | **Total Capital Raise** | **12,500,000** | — | **Rs. 25,00,00,000** | * **Warrant Terms:** Holders paid **25%** upfront, with the remaining **75%** payable upon conversion within **18 months**. * **Compliance:** The issue follows **SEBI (ICDR) Regulations 164 and 166A**, ensuring pricing is at or above the mandated **floor price**. * **Dematerialization:** All equity shares are fully dematerialized under **ISIN INE730E01016**, with connectivity to **NSDL and CDSL**. --- ### **Service Verticals: Financial & Advisory Portfolio** Despite the pivot to healthcare, the company maintains a robust professional services arm that caters to **SMEs** and large corporations. | Service Vertical | Key Offerings | Primary Objective | | :--- | :--- | :--- | | **Audit & Assurance** | Statutory, Internal, Tax, and Transfer Pricing audits | Regulatory compliance and risk assessment | | **Corporate Finance** | Debt syndication, PE advisory, and Valuations | Capital raising and business growth | | **Outsourcing (FAO)** | End-to-end Accounting and Finance processes | Operational efficiency for global clients | | **Tax & Advisory** | Tax planning and Regulatory compliance | Legal adherence and strategic positioning | --- ### **Operational Infrastructure and Governance** The company employs a structured framework to ensure asset integrity and regulatory adherence: * **Asset Management:** Fixed assets undergo physical verification in a **phased three-year cycle**. As of **May 2025**, all title deeds for immovable properties are held directly in the company’s name. * **Leadership:** The board has been strengthened with the appointment of **Ms. Sakshi Laller** as **Whole Time Director** (tenure through **May 2028**) and **Mr. Vishwambhar Dayal Gupta** as Promoter Non-Executive Director. * **Financial Reporting:** Statements are prepared per **Ind AS** and **Section 133 of the Companies Act, 2013**. While the company is not currently required to maintain statutory **cost records** under Section 148(1), it maintains internal controls commensurate with its **size and scale**. --- ### **Risk Profile and Mitigation Strategies** Management identifies and monitors several critical risks that could impact the company's "going concern" status: * **Market & Technical Risks:** Pricing pressures from **low-cost global suppliers** and the necessity for rapid **technology upgrades** in the pharma sector. * **Regulatory Compliance:** The company has noted historical delays in **SEBI (LODR)** filings (e.g., Shareholding Patterns and Corporate Governance reports for **June/September 2024**). Management is actively addressing these secretarial lapses to align with **BSE** and **MSEI** listing agreements. * **Related Party Transactions (RPT):** High volume of transactions with related entities, with a proposed aggregate value of **Rs. 60 crores** for **FY 2024-25**, conducted at **Arm’s Length**. * **Geopolitical/Resource Risks:** Potential operational impacts from inter-state water disputes (e.g., **Punjab vs. Rajasthan** water cess), which may affect utility costs or regional stability. **Financial Health Summary** | Metric | Status / Value | | :--- | :--- | | **Net Profit/Loss (FY 22-23)** | **(Rs. 7,64,209)** | | **Current Focus** | **Cost optimization** and performance improvement | | **Revaluation of PPE** | **No revaluation** as of March 2025 | | **Loans/Guarantees (Sec. 186)** | **Nil** for the most recent review period | --- ### **Future Outlook** Prism Medico and Pharmacy Limited is positioned as a turnaround story. By leveraging management’s cross-industry expertise in **finance, technical, and administrative** sectors, the company aims to mitigate the "unusual phases" of its recent transition. The **Rs. 25 Crore** capital infusion serves as the primary catalyst for scaling its new pharmaceutical operations while maintaining its legacy advisory revenue streams.